Articles tagged with Alzheimer Disease
Two rare variants in the AKAP9 gene are associated with an increased risk of Alzheimer's disease in African Americans. Carriers of these variants have a 2.8-3.6 times greater risk of developing AD.
UH undergrads worked on diverse projects tackling cancer, Alzheimer's disease, and contact lens issues. Researchers explored ways to convert cancer cells into fat cells, analyzed neural activity effects of alcohol, and created a Lego-building guide app.
High-field nuclear magnetic resonance spectroscopy (≥ 7.0T) detected abnormalities in the hippocampus of Alzheimer's disease rats, including reduced N-acetylaspartate wave crest, elevated creatine and choline wave crest, and neuronal shrinkage.
Scientists at the Salk Institute have discovered a compound in the Voacanga africana plant that protects cells from altered molecular pathways linked to neurodegenerative diseases. The compound, voacamine, has shown anti-inflammatory and neuroprotective effects, suggesting potential as a treatment for Alzheimer's, Parkinson's, and stroke.
A telephone-based support program has been shown to significantly reduce depression and symptoms in informal caregivers of individuals with dementia. This study, published in the journal Alzheimer's & Dementia, highlights the benefits of convenient and accessible support for caregivers who often face significant pressure and stress.
A new study by Rush University Medical Center researchers found that depression is independently associated with an increased risk of developing dementia. The study suggests that targeting and treating depression could help prevent or delay cognitive decline in older adults.
A new gene variant, PLXNA4, has been linked to an increased risk of developing Alzheimer's disease. The study found that this gene affects the processing of tau protein, a key hallmark of the disease. This discovery may lead to the development of targeted drug treatments for AD.
Researchers found that patients with dementia were more likely to receive a pacemaker, even after adjusting for clinical risk factors. The study suggests that patients with serious life-limiting illnesses may be treated more aggressively than expected.
A recent study published by researchers from UC Davis Alzheimer's Disease Center and the University of Victoria found that early life experiences, such as childhood socioeconomic status and literacy, have a greater influence on the risk of cognitive impairment late in life than demographic characteristics like race and ethnicity. The s...
Researchers at Boston University School of Medicine have discovered that pre-treatment with the anti-aging protein Klotho can prevent neuron death in the presence of toxic amyloid and glutamate. This finding suggests a potential treatment approach for Alzheimer's disease, which affects millions of Americans.
Scientists have identified a potential oral therapy for Alzheimer's disease using compounds initially developed for cancer treatment. The study found that these molecules can stabilize microtubules in the brain, which are critical for transporting nutrients and other essential molecules.
Researchers found that an enzyme called acid sphingomyelinase (ASM) disrupts autophagy in patients with Alzheimer's disease, leading to toxic protein accumulation. Reducing ASM activity restored autophagy and improved memory in mice with AD-like disease.
Researchers from NYU Langone will present new findings on tau immunotherapy and its potential for treating Alzheimer's disease. The presentations focus on the role of mitochondria and death receptors in amyloid toxicity, which may lead to improved treatment options for patients.
A study published in Neural Regeneration Research found that acupuncture and moxibustion can reduce neuronal edema in Alzheimer's disease rats. The treatment modality targets axin and β-catenin protein expression, a key pathway involved in Wnt signaling.
Researchers found that bexarotene reduces levels of neurotoxic protein amyloid-beta in mice with late-stage Alzheimer's, but increases it during early stages. This suggests that treatment timing and duration may be crucial for effectiveness.
A new study found that regular use of fish oil supplements was associated with a significant reduction in cognitive decline and brain atrophy in older adults. The study also showed that participants who took fish oil supplements demonstrated less brain shrinkage compared to those who did not use the supplements.
Researchers found that taking B vitamins had no effect on cognitive decline or reducing the risk of Alzheimer's disease in a meta-analysis of 11 clinical trials involving 22,000 participants. The study suggests that folic acid and vitamin B-12 can lower homocysteine levels, but not prevent the disease.
A genetic variant in the HMG CoA reductase gene has been identified as a significant protector against common Alzheimer's disease, delaying its onset by up to 4 years. This breakthrough discovery opens up new possibilities for treatment and pharmaceutical interventions.
Scientists transplanted inhibitory neuron progenitors into two mouse models of Alzheimer's disease, improving learning and memory abilities. The treatment replenished brain cells lost due to apoE4, regulating brain activity.
Research at the Alzheimer's Association International Conference 2014 found that participating in mentally stimulating activities and moderate physical exercise in middle age may help protect against Alzheimer's disease. Additionally, high blood pressure was seen to protect against cognitive decline in people aged 90 and older.
A new noninvasive optical imaging device has been shown to detect changes in the retina that occur before clinical diagnosis of Alzheimer's disease. The device, developed at Cedars-Sinai, can differentiate between Alzheimer's and non-Alzheimer's diseases with high sensitivity and specificity.
Research trials report associations between decreased odor identification and loss of brain cell function, as well as beta-amyloid buildup in the eye with progression to Alzheimer's. Early detection is crucial for intervention and prevention, with promising results suggesting potential methods for early detection in a research setting.
Transplantation of adipose-derived stem cells (ADSCs) into APP/PS1 transgenic AD model mice promoted neurogenesis in the subgranular and subventricular zones. This improved cognitive function and reduced oxidative stress, providing evidence for AD treatment with ADSCs.
A novel AD vaccine, Plp-Adeno-X-CMV-(Aβ3-10)10-CpG, was administered via nasal mucosal inhalation to AD transgenic mouse models, producing strong T helper 2 humoral immune responses and reducing Aβ1-42-induced cytotoxicity. This approach offers a promising therapeutic strategy for Alzheimer's disease.
Researchers will analyze data from 6,000 patients with Alzheimer's and 5,000 elderly individuals without the disease to identify rare genetic variants that may protect or contribute to risk. The project aims to develop novel approaches to delay or prevent Alzheimer's disease.
Scientists have identified a novel mechanism of memory loss in Alzheimer's disease and propose new therapeutic targets, including the production and release mechanisms of GABA in reactive astrocytes. A MAO-B inhibitor showed promise in treating Alzheimer's disease model mice for a short time.
Researchers will analyze whole exome and whole genome sequence data from 6,000 volunteers with Alzheimer disease and 5,000 older individuals without the disease to identify rare genetic variants. The goal is to search for therapeutic targets that might reduce the economic and human burden of this devastating disease.
A team of researchers from the University of Pennsylvania and four other American universities will analyze genetic data from 6,000 individuals with Alzheimer's disease and 5,000 older individuals without the disease. The goal is to identify rare genetic variants that may protect against or contribute to the disease risk.
Researchers at the University of Pennsylvania School of Medicine will analyze whole exome and genome sequence data from 6,000 volunteers with Alzheimer's disease to identify rare genetic variants. The goal is to find new therapeutic targets that can reduce the economic and human burden caused by this devastating disease.
Alzheimer's disease is a neurodegenerative disorder characterized by memory problems, orientation issues, and behavioral changes. A simplified diagnosis using specific biomarkers improves the accuracy of early-stage diagnoses.
Researchers at Case Western Reserve University will analyze genetic data from 11,000 individuals to identify rare variants that may protect or contribute to Alzheimer's risk. The goal is to illuminate the genetic architecture of Alzheimer's and discover therapeutic targets.
The NIH awards grants for analyzing genome sequence data to identify rare genetic variants that protect against or contribute to Alzheimer's disease. The projects will also explore differences in data from different racial/ethnic groups and examine the association between brain images and genome sequences.
Researchers from Boston University School of Medicine will analyze genomic data from 11,000 individuals to identify rare genetic variants that may protect against or contribute to Alzheimer's disease risk. The study aims to uncover the biological pathways underlying the disease and potentially lead to novel therapeutic targets.
Two studies using different mouse models confirm that comorbid Alzheimer's disease and cerebrovascular disease significantly worsen learning and memory outcomes in mice. Researchers say the findings have potential implications for patients with both disorders, who account for approximately 40% of Alzheimer's cases.
Researchers discovered that amyloid-beta binds to pairs of APP molecules, triggering a signalling cascade that causes elevated neuronal activity in the hippocampus. This hyperactivity damages memory and learning functions and is observed in patients with mild cognitive impairment and early stages of Alzheimer's disease.
A potential Alzheimer's drug has been identified that prevents abnormal blood clots in the brain, which contribute to memory loss and cognitive decline. The compound, RU-505, targets amyloid-β's role in forming clots and shows promise in both test tube experiments and mouse models.
A study found that Lavado cocoa extract reduces β-amyloid formation, which damages nerve cells in Alzheimer's disease. The extract also rescues synaptic function, a potential target for an effective Alzheimer's disease drug.
A self-repairing mechanism known as neurogenesis partially counteracts neuronal loss in neurodegenerative diseases. Newborn neurons generated in the dentate gyrus integrate into brain circuitry, maintaining some functions at early stages of disease progression.
Researchers propose a public-private partnership to fund diverse drug-discovery projects simultaneously, increasing the chances of therapeutic breakthroughs. The model estimates a double-digit return on public investment over the long run.
A new study suggests that blocking endocannabinoids, the brain's internal versions of marijuana's psychoactive chemicals, may trigger early Alzheimer's deficits. A-beta, a substance strongly suspected to play a key role in Alzheimer's, impairs learning and memory by blocking endocannabinoids' beneficial action in the brain.
Researchers have identified a fast-acting compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine without unwanted side effects. HNK also shows promise in treating neurodegenerative disorders like Alzheimer's and Parkinson's diseases.
A research team led by Gong Chen has discovered a novel biomarker that targets excessive GABA inhibition in the brain's dentate gyrus, which correlates with poor memory performance in Alzheimer's disease models. Reducing this inhibitory neurotransmitter may lead to a new therapy for Alzheimer's disease.
Researchers link late-life depression to accelerated Alzheimer's disease development through beta-amyloid accumulation. Mild cognitive impairment patients with depressive symptoms showed higher amyloid deposition than non-depressed controls.
A novel F-18 labeled tracer, F-18 THK5117, selectively binds to tau/neurofibrillary tangles in Alzheimer's brains. This study demonstrates the potential for F-18 THK5117 to develop new anti-dementia drugs.
Researchers at Johns Hopkins Medicine have plotted the complex paths of cholinergic neurons, which degenerate first in people with Alzheimer's. The study reveals that these neurons face significant challenges due to their thin pipeline and numerous branch points.
A new diagnostic tool, combining data from multiple sources, can help clinicians diagnose Alzheimer's disease, frontotemporal dementia, and mild cognitive impairment with a Disease State Index. The tool also provides a visual representation of the findings in a Disease State Fingerprint.
Researchers discovered that mesenchymal stem cells can enhance hippocampal neurogenesis and neuronal differentiation by augmenting the Wnt signaling pathway, a key player in Alzheimer's disease. This finding could lead to improved treatment strategies for the disease.
A new study suggests that light treatment tailored to increase circadian stimulation during the day can improve sleep quality, efficiency, and total sleep duration. The research also shows significant reductions in scores for depression and agitation.
Researchers at Allen Institute for Brain Science will map connectivity patterns across whole brain in mouse models of Alzheimer's disease. The goal is to understand pathways through which the disease spreads and develop effective treatments.
Scientists have identified a compound, 2-PMAP, that reduces amyloid proteins in the brain by over half and may be safe enough to be taken daily. The researchers hope it could be used to ward off Alzheimer's disease.
Scientists successfully erased and reactivated memories in rats by applying specific frequencies of light and electrical stimuli to the brain. This breakthrough study offers new hope for treating Alzheimer's disease, as it shows promise in strengthening or weakening synaptic connections that are weakened in the condition.
Researchers at Scripps Research Institute found that a protein with a propensity to form aggregates protects against Alzheimer's disease when produced in the brain. Boosting its production specifically in neurons could help ward off Alzheimer's disease, according to the study published in the Journal of Neuroscience.
University of Missouri researcher James Lee has been awarded a $1.5 million NIH grant to investigate the link between amyloid-beta peptide and blood capillary damage in Alzheimer's patients. His study seeks to understand how A-beta interacts with cerebral endothelial cells, leading to cell breakdown and neuronal degeneration.
A molecular compound developed by Saint Louis University scientists has restored learning, memory, and appropriate behavior in a mouse model of Alzheimer's disease. The compound also reduced inflammation in the brain responsible for learning and memory.
Researchers developed a new cognitive test that can accurately distinguish between memory impairments caused by very mild Alzheimer's disease and those due to normal aging. The test assesses relational memory abilities and reveals unique impairments specific to Alzheimer's, allowing for more precise diagnosis.
Researchers found that antidepressant citalopram reduced amyloid beta production in mice and humans, potentially slowing Alzheimer's progression. The study suggests a possible new treatment approach for the devastating disease.
A University of Pennsylvania researcher discovered that the common selective serotonin reuptake inhibitor (SSRI) citalopram arrested the growth of amyloid beta, a peptide in the brain thought to trigger Alzheimer's development. Citalopram was shown to reduce A-beta concentration and prevent new plaque development in mice and humans.
Researchers investigated the connection between small-vessel disease and Alzheimer's disease pathology, revealing a possible correlation with cognitive impairment. The study found that small vessel disease may contribute to the development of Alzheimer's-like pathology in the brain.
Researchers discovered that people with a variant of the longevity gene KLOTHO have improved brain skills, such as thinking and learning, which decreases with age. Increasing KLOTHO levels in mice may boost cognitive abilities by strengthening connections between nerve cells.
A gene variant linked to longevity may also improve learning and memory, according to a new study. Researchers found that individuals carrying the KL-VS variant of the KLOTHO gene performed better on cognitive tests.